Rani Therapeutics Holdings Inc

Stock Chart, Company Information, and Scan Results

$0.87(as of Apr 29, 3:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Rani Therapeutics Holdings Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$0.87
Ticker SymbolRANI
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees69
CountyUSA
Market Cap$111.2M
EBIDTA-37.4M
10-Day Moving Average0.93
P/E Ratio-4.30
20-Day Moving Average0.87
Forward P/E Ratio0.00
50-Day Moving Average1.09
Earnings per Share-0.45
200-Day Moving Average1.10
Profit Margin-705.41%
RSI41.96
Shares Outstanding99.8M
ATR0.09
52-Week High3.87
Volume361,894
52-Week Low0.39
Most Recent Support Level0.71
Book Value41.5M
Most Recent Resistance Level0.98
P/B Ratio3.08
Upper Keltner1.07
P/S Ratio78.19
Lower Keltner0.66
Debt-to-Equity Ratio1.07
Next Earnings Date05/13/2026
Cash Surplus5.9M
Next Ex-Dividend DateUnknown

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings Inc In Our Stock Scanner

As of Apr 29, 2026
example chart graphic
Scan Name: Discounted Stocks with Earnings GrowthScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Death CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.